| Document |
Document Title |
|
WO/2023/219584A1 |
The invention relates to a thiosemicarbazone complex compound with anti¬ inflammatory and wound healing properties, which inhibits the 3CL main protease enzyme of SARS-CoV-2 virus and IL-8 cytokine of human bronchial epithelial cells. T...
|
|
WO/2021/209859A1 |
Monomers, polymers formed from such monomers, and articles for biomaterial capture including such polymers, wherein the monomer is represented by the following general Formula (I): CH2=CR1-C(=O)-X-R2-Z-X3-NR3-C(=X2)-X1-R4, wherein: R1 is...
|
|
WO/2021/168903A1 |
Provided are an S-substituted-thiosemicarbazone structure compound shown in a formula I and a preparation method and an application thereof. The S-substituted-thiosemicarbazone compound shown in the formula I has an excellent prevention ...
|
|
WO/2021/162650A1 |
The present invention provides 5-fluoro/5-trifluoromethoxy-lH- indole-2,3-dione 3-(4-phenylthiosemicarbazone) derivatives of formula (IV) as interleukin 1 (IL-1) antagonists and anti-pyretic and/or anti-inflammatory agents for use in a m...
|
|
WO/2021/041852A1 |
The disclosure provides a method for preventing or treating a flavivirus infection, a filovirus infection, a SARS-CoV-1 infection, a SARS-CoV-2 infection, or a MERS-CoV infection, the method comprising administering to a subject in need ...
|
|
WO/2019/235569A1 |
The present invention addresses the problem of providing: a novel kinase inhibitor and others; and a therapeutic agent for a disease, a drug discovery screening method and others, each utilizing the inhibitor and others. A compound repre...
|
|
WO/2019/055493A1 |
A method for treating a mitogen activated protein kinase kinase/extracellular signal-regulated kinase ("MEK")-induced or an MEK-related pathology in a mammal, comprising administering a pharmaceutical composition containing an effective ...
|
|
WO/2019/018377A1 |
Pro-chelator compositions featuring disulfide masks that upon activation yield active chelators. The pro-chelator compositions may be activated intracellularly, for example within cells featuring metal ion dysregulation, cells that proli...
|
|
WO/2018/204564A1 |
Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I) or (la)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments...
|
|
WO/2018/092085A1 |
The technical solution relates to the field of medicine, and particularly to means for treating tuberculosis. A pharmaceutical composition for treating tuberculosis contains an active ingredient and at least one pharmaceutically acceptab...
|
|
WO/2018/092077A1 |
The technical solution relates to the field of medicine, and particularly to means for treating tuberculosis. A pharmaceutical composition for treating tuberculosis contains an active ingredient and at least one pharmaceutically acceptab...
|
|
WO/2018/043399A1 |
[Problem] To provide a novel therapeutic agent for diabetes which can be less apt to produce side effects such as persistent hypoglycemia. [Solution] A compound characterized by containing a derivative of 1,1-diphenylsemicarbazide or 1,1...
|
|
WO/2017/214680A1 |
The present invention relates to new multi-functional compounds that are useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease, to the preparation of the compounds, and to compositions including the compounds...
|
|
WO/2017/099695A1 |
N-[(aminosulfonyl)phenyl]-2-(1,2-dihydro-2-oxo-3H-indol-3-yl
idene)-hydrazinecarbothioamide derivatives of the following formula (III) for treating cancer and immunological disorders. R5, R6 and R7 are each independently selected from hy...
|
|
WO/2017/070752A1 |
The present invention provides certain thiosemicarbazone metal complexes which have advantageous properties in medical imaging. The thiosemicarbazone metal complexes can be safely and easily produced in real time, administered quickly af...
|
|
WO/2017/030983A1 |
This present disclosure is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin L, cathepsin K, and/or cathepsin B, will be thera...
|
|
WO/2016/111658A1 |
The present invention relates to the synthesis method of thiosemicarbazone derivatives comprising sulphonamide group and having high anticonvulsant/antiepileptic activity.
|
|
WO/2016/041972A1 |
The present invention relates to benzothiophene, benzyloxybenzylidene and indoline-2-one derivatives and the use of said derivatives in the treatment and/or prevention of tuberculosis.
|
|
WO/2016/033635A1 |
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in ...
|
|
WO/2014/198241A1 |
Provided is a process for preparing a compound shown as formula (I), comprising a step of contacting a compound shown as formula (II) or a salt thereof with a brominating agent, wherein R1is OR2 or NR3R4; R2 is C1-C6 alkyl or phenyl; eac...
|
|
WO/2014/176636A9 |
The invention provides compounds of Formula (I), and methods of treating or preventing a bacterial infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufactur...
|
|
WO/2013/169361A1 |
The present invention relates to chelator compounds for chelating metal ions. In particular, the present invention relates to (thio)semicarbazone compounds and (thio)hydrazone compounds, such as PpYeT and PpYaT, which are chelators for m...
|
|
WO/2013/158803A1 |
The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging canc...
|
|
WO/2013/142038A2 |
This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.
|
|
WO/2013/111798A1 |
[Problem] To provide a novel serine racemase inhibitor having a satisfactory activity and satisfactory specificity. [Solution] A serine racemase inhibitor comprising at least one compound selected from a compound group consisting of comp...
|
|
WO/2012/105438A1 |
An electrode active material having a dithionic structure indicated in general formula. The dithionic structure has a linking group (Z) interposed between X=S groups (X: C or Si). The linking group (Z) is CH2, CF2, O, S, SO2, Se, or N-R'...
|
|
WO/2012/018757A1 |
The present invention discloses processes for forming polythiol compositions from olefinic hydrocarbons such as cyclooctadiene, cyclododecatriene, and trivinylcyclohexane. The polythiol compositions produced from these processes, includi...
|
|
WO/2011/026193A1 |
The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt or solvate or thereof. In particular, the present invention relates to a method treating diseases involving cell proliferation, migr...
|
|
WO/2010/066010A1 |
The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), compounds useful as synthetic intermediates in the method, new bis(thiosemicarbazones) that can be readily accessed by use of the method and method...
|
|
WO/2009/096039A1 |
A compound useful as an intermediate for obtaining a thiadiazole-based acaricide having a high purity in a high yield. This intermediate is obtained, for example, by reacting a 2-(4-hydroxyphenoxy)propionic acid ester represented by the ...
|
|
WO/2008/025941A2 |
The invention provides metal complexes of formula (I), wherein M is a transition metal or a p-block metal, and a, b, c, n, L, X, X', Y, Y', L1, L1', R1, R1', R2 and R2' are defined herein. Such complexes are useful in medical imaging and...
|
|
WO/2008/024304A2 |
Disclosed are compounds of formula (IA), formula (IV) or formula (V), wherein the variables are as defined herein, and pharmaceutical compositions containing them which are useful for treating a subject with a proliferative disorder, suc...
|
|
WO/2006/116816A1 |
The present invention relates to a storage stable dithizone preparation, whereby the dithizone preparation is in a form that is ready for use to detect the presence of transition metal ions in a sample. The present invention also relates...
|
|
WO/2006/093124A1 |
It is intended to provide a novel free radical scavenger for removing active oxygen which is causative for various diseases in vivo and results in degradation and color fade-out in commercial products. A free radical scavenger which cont...
|
|
WO/2006/041119A1 |
Compounds represented by the general formula (1) or salts thereof, or hydrates of both, which are safe and have moderate physicochemical stability and which are useful as preventive or therapeutic agents for diseases caused by thrombus f...
|
|
WO/2006/019955A2 |
Disclosed herein are antiviral compounds, such as anti-human cytomegalovirus antiviral compounds, pharmaceutical compositions and antiviral methods.
|
|
WO/2005/087211A1 |
The present invention provides a novel class of compounds that disrupt the parasitic infectious life cycle and serve as promising agents for anti-parasitic therapy.
|
|
WO/2005/009940A1 |
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
|
|
WO/2004/062601A2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...
|
|
WO/2003/078386A1 |
The present invention relates to novel naphthyl semicarbazone, naphthylhydrazone, naphthyl thiosemicarbazone, and naphthyl thiohydrazone compounds. The invention also relates to therapeutic uses of such compounds and&sol or their iron co...
|
|
WO/2003/000647A1 |
The invention relates to a novel class of ligands, complexes comprising such ligands and a metal ion, and adducts of these metal complexes and a macromolecule. Pharmaceutical compositions and methods of making and using the ligand-metal ...
|
|
WO/2002/098420A1 |
The present invention is directed to optionally substituted 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs thereof, represented by the Formulae (I) and (II), wherein A¿1,?...
|
|
WO/2002/096867A2 |
The present invention is directed in part towards methods of modulating the function of protein kinases with phenol- and hydroxynaphthalene-based compounds. The methods incorporate cells that express a protein kinase. In addition, the in...
|
|
WO/2002/092019A2 |
Halogenated derivatives of two synthetic anti-tuberculosis agents, thioacetazone and $i(p)-aminosalicylic acid, have been synthesized. In general, the halogenated compound has the structure of Structure (I), wherein X¿1? is a halogen an...
|
|
WO/2002/081438A2 |
A process is provided for producing a thiosemicarbazide which includes the steps of reacting an alkylamine with carbon disulphide in the presence of a base selected from N,N-diisopropylethylamine and N,N,-diisopropyl-methylamine to produ...
|
|
WO/2002/078696A1 |
Compounds of this invention are non-peptide, reversible inhibitors of type (2) methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma proliferative retinopathy, rheumatoid arthritis...
|
|
WO/2002/059080A2 |
The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invent...
|
|
WO/2002/049413A2 |
Invented are non-peptide TPO mimetics. also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted thi...
|
|
WO/2002/044126A2 |
The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins. In the compounds of this invention, at least two carbo-or heterocyclic groups are attached ...
|
|
WO/2002/042254A1 |
The present invention relates to a process of producing carbonyl a-substituted nitrogen-containing compounds, which comprises reacting a-halo-ketone or a-halo-aldehyde with primary amine, secondary amine or heterocycle compound containin...
|
